MicroPort Scientific (0853) AI Stock Analysis

• Market Cap: HK$19.48B
• Dividend Yield: N/A
• Average Volume (3M): 25.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: -1.04%
• EPS Growth: 60.66%
• Country: HK
• Employees: 6,347
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.22
• Shares Outstanding: 1,917,257,700
• 10 Day Avg. Volume: 21,967,342
• 30 Day Avg. Volume: 25,373,873
• PEG Ratio: 0.12
• Price to Book (P/B): 2.40
• Price to Sales (P/S): 1.40
• P/FCF Ratio: -9.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.05
• Revenue Forecast (FY): HK$1.26B

• Rating: 46 Neutral
• Price Target: HK$12.50 ▲(7.11% Upside)
• Action: Upgraded Date: 12/03/25
• Date: Action: Upgraded 12/03/25

The overall stock score is primarily impacted by significant financial challenges, including persistent losses and liquidity issues. Technical analysis provides a slightly more balanced view, but the negative valuation metrics further weigh down the score. The absence of earnings call insights and corporate events means these factors do not influence the score.

Positive Factors

Product Diversification

A broad product portfolio across cardiovascular, orthopedics and neurosurgery reduces reliance on any single market and supports multiple durable revenue streams. This diversification aids resilience to sector-specific cycles and creates cross-selling and bundled-service opportunities over months to years.

R&D and Innovation Focus

An explicit strong R&D focus supports a sustainable pipeline of differentiated medical devices, helps meet evolving regulatory and clinical standards, and underpins long-term product-driven competitive advantage and margin preservation versus low-cost competitors.

Established Commercial Channels & Partnerships

Established distributor relationships, hospital channels and research collaborations expand market reach and lower customer acquisition costs. Durable partnerships support recurring maintenance/service revenue and licensing opportunities, improving predictability of sales over a multi-quarter horizon.

Negative Factors

Persistent Unprofitability

Sustained negative EBIT and net losses indicate structural operational inefficiencies. Ongoing unprofitability constrains internal reinvestment, undermines margin sustainability, and forces dependence on external capital, which can impede strategic initiatives and long-term competitiveness.

High Leverage and Weak Equity

Rising debt and declining shareholders' equity raise solvency and refinancing risk. Higher leverage increases fixed costs and reduces financial flexibility to fund R&D, commercial expansion, or absorb reimbursement shocks, posing a durable constraint on strategic options.

Negative Operating Cash Flow

Consistent negative operating and free cash flows mean operations do not self-fund growth. Reliance on financing increases liquidity and covenant risk, limits runway for product commercialization, and can force dilutive or restrictive financing solutions that impair long-term value creation.

MicroPort Scientific Business Overview & Revenue Model

Company Description

MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment offers products and services for the treatment of coronary artery-related diseases; coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for neurovascular diseases. Its Heart Valve Business segment provides VitaFlow Transcatheter aortic valve and delivery system, VitaFlow Liberty Transcatheter aortic valve implantation and retrievable delivery systems, Alwide Plus Balloon Catheter, various transcatheter aortic valve implantation, transcatheter mitral valve, transcatheter tricuspid valve, and surgical valve products. The company's Surgical Robot Business segment designs, develops, and commercializes surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

MicroPort Scientific generates revenue through the sale of its medical devices across various sectors, including cardiovascular, orthopedics, and neurosurgery. The company has established key revenue streams from direct sales to hospitals and healthcare providers, as well as partnerships with distributors and healthcare organizations that facilitate the distribution of its products. Significant partnerships with international medical institutions and collaborations with research entities also contribute to its earnings, as they enhance product development and market reach. Additionally, the company benefits from ongoing revenue through product maintenance and support services, as well as potential royalties from licensing agreements related to its innovative technologies.

MicroPort Scientific Financial Statement Overview

Summary

MicroPort Scientific faces considerable financial challenges characterized by persistent losses, high leverage, and cash flow issues. Despite revenue growth, the company's profitability and liquidity remain weak, necessitating strategic improvements in cost management and operational efficiency to stabilize its financial position.

Income Statement

The income statement shows significant challenges in profitability, with a negative net income and EBIT over the past three years. Although there has been a revenue growth trend from 2020 to 2024, the company has consistently reported negative EBIT and net profit margins, indicating persistent operational inefficiencies and cost management issues.

Balance Sheet

The balance sheet highlights a concerning increase in total debt over the years, contributing to a high debt-to-equity ratio. Stockholders' equity has decreased significantly, reflecting financial instability. The equity ratio has also declined, indicating a heavier reliance on debt financing. These factors suggest potential solvency risks.

Cash Flow

The cash flow statement reveals negative operating cash flows, which paired with consistent negative free cash flows, indicates liquidity challenges. The company has been unable to generate positive cash flows from operations, relying heavily on financing activities to sustain operations, which poses a risk to financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.02B	1.03B	950.73M	840.83M	778.64M	648.73M
Gross Profit	552.09M	574.09M	532.10M	501.77M	491.77M	436.03M
EBITDA	-13.83M	-45.30M	-382.54M	-430.26M	-256.35M	-106.87M
Net Income	-163.81M	-214.04M	-477.63M	-436.51M	-276.48M	-191.25M
Balance Sheet
Total Assets	3.77B	3.63B	3.93B	3.99B	4.38B	2.47B
Cash, Cash Equivalents and Short-Term Investments	957.62M	974.48M	1.06B	1.24B	1.75B	1.00B
Total Debt	1.76B	1.69B	1.70B	1.47B	1.24B	296.31M
Total Liabilities	2.59B	2.49B	2.53B	2.20B	2.16B	1.08B
Stockholders Equity	623.12M	603.47M	757.82M	1.14B	1.49B	1.13B
Cash Flow
Free Cash Flow	-83.89M	-158.10M	-430.99M	-600.58M	-505.45M	-143.58M
Operating Cash Flow	-27.76M	-49.67M	-231.87M	-343.30M	-257.53M	-23.20M
Investing Cash Flow	16.02M	-149.73M	-376.81M	-412.75M	-655.74M	-148.13M
Financing Cash Flow	37.18M	-97.92M	434.90M	273.00M	1.66B	846.89M

MicroPort Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0853, the sentiment is Negative. The current price of 11.67 is above the 20-day moving average (MA) of 10.97, above the 50-day MA of 11.33, and above the 200-day MA of 11.14, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 33.51 is Neutral, neither overbought nor oversold. The STOCH value of 14.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0853.

MicroPort Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	69 Neutral	HK$6.60B	9.76	11.24%	1.26%	25.18%	55.79%
1858	69 Neutral	HK$7.84B	19.30	8.69%	1.88%	14.56%	61.60%
2172	69 Neutral	HK$6.08B	18.40	11.79%	1.50%	-5.18%	-9.69%
1302	57 Neutral	HK$6.87B	36.52	1.98%	―	3.42%	-70.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0853	46 Neutral	HK$19.48B	-9.88	-24.77%	―	-1.04%	60.66%
2252	46 Neutral	HK$24.63B	-33.53	-117.51%	―	112.97%	37.70%

MicroPort Scientific Corporate Events

MicroPort Scientific Flags Return to Profit on Overseas Growth and Cost Cuts

MicroPort Scientific has issued a positive profit alert, stating that it expects to swing to a net profit of at least US$20 million for the year ended 31 December 2025, compared with an audited net loss of about US$268 million a year earlier. The turnaround is attributed to roughly 70% year-on-year revenue growth in its overseas “going‑abroad” business, a 2–3 percentage-point improvement in gross margin from cost optimisation despite domestic pricing pressure in China, a 10–11% reduction in operating expenses through lean management and higher efficiency, and gains from the disposal of subsidiaries, collectively signalling a significant improvement in operational performance and financial health ahead of the full 2025 results due by end-March 2026.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

MicroPort Deconsolidates Neuro Device Subsidiary After Loss of Board Control

MicroPort Scientific has deconsolidated its subsidiary MicroPort NeuroScientific Corporation after the appointment of an independent non-executive director shifted the balance of control on the Target Company’s board, leaving MicroPort with significant influence but no longer accounting control. As a result, MicroPort will treat the neuro-interventional device maker as an associate rather than a subsidiary, and expects to recognize a deemed gain on disposal in its consolidated financial statements, calculated with reference to the fair value of its remaining equity stake and the Target Company’s net assets, which were about RMB1.72 billion as of 30 June 2025; the gain remains subject to audit and may affect reported earnings and balance sheet structure.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

MicroPort Scientific Announces Strategic Merger to Enhance Competitiveness in Cardiovascular Devices

MicroPort Scientific Corporation announced the approval of a strategic merger between its CRM business and MicroPort CardioFlow, expected to be completed by December 19, 2025. This merger aims to optimize resource allocation, enhance competitiveness, and strengthen synergies in structural heart disease and CRM. By integrating complementary product lines and leveraging global resources, the company plans to accelerate market penetration and improve operational efficiency. The merger will also optimize the company’s financial structure by converting preferred shares into ordinary shares, reducing financial liabilities, and refinancing existing debt. This strategic move positions MicroPort as a leader in heart failure management, expanding its business layout and enhancing its competitiveness in the cardiovascular device market.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

MicroPort Scientific Reports Mixed Financial Results for Endovastec

MicroPort Scientific has released the unaudited financial results for its subsidiary, Shanghai MicroPort Endovascular MedTech (Endovastec), for the nine months ending September 30, 2025. The results show a modest revenue increase of 4.66% compared to the same period in 2024, but a significant decline in profit by 21.80%. Despite the profit drop, Endovastec’s total assets grew by 10.27%, indicating a strong asset base. Investors are advised to exercise caution as these figures are unaudited and do not represent the full scope of the Group’s operations.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.